Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 15c; Offers FY23 Revenue Guidance

May 4, 2023 8:22 AM EDT

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.46), $0.15 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $95.3 million versus the consensus estimate of $91.4 million.

GUIDANCE:

Intra-Cellular Therapies sees FY2023 revenue of $430-455 million, versus the consensus of $448... More